Taken together with the unknown impact of midostaurin and gemtuzumab ozogamicin on overall AML outcome assessment, 2022 ELN recommendations removed the FLT3-ITD allelic ratio from upfront risk appraisal [22]. The gene discussed is FLT3; the disease is acute myeloid leukemia.